Out of ‘Stealth’ Mode, QurAlis Expects First QRL-201 Trial in 2022
QurAlis is advancing the development of QRL-201, its “groundbreaking” lead treatment candidate for amyotrophic lateral sclerosis (ALS), and…
Articles by Marta Figueiredo, PhD
Phase 1b Trial of Oral DNL343 in ALS Patients Begins Dosing
A Phase 1b clinical trial evaluating the safety and pharmacological profile of DNL343, Denali Therapeutics’ investigational oral therapy, in…
Amylyx Plans to File for Approval of AMX0035 in US
Amylyx Pharmaceuticals plans to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in…
Subtle Changes in MicroRNA-218 May Fuel ALS
Dropping the levels of microRNA-218 (miR-218) — a small molecule that regulates the activity of other genes — below a…
Masitinib Helps Keep Inflammatory Mast Cells From Spinal Cord
Mast cells, a type of immune cell, infiltrate the spinal cord of amyotrophic lateral sclerosis (ALS) patients and rodent…
Phase 3 Trial of Ultomiris in ALS Patients Stopping for Lack of Efficacy
Alexion Pharmaceuticals is stopping further work on Ultomiris (ravulizumab) — its approved therapy for complement-associated rare blood disorders —…
COMBAT-ALS Trial Still Enrolling in North America
MediciNova is still recruiting adults with early-stage amyotrophic lateral sclerosis (ALS) for the COMBAT-ALS Phase 2b/3 clinical trial…
Radicava Prolongs Survival, Small ALS Study Shows
Long-term treatment with Radicava (edaravone) is generally safe and nearly doubles survival time in adults with amyotrophic lateral…
Dosing of SLS-005 to Soon Begin in Phase 2b/3 HEALEY ALS Trial Arm
Seelos Therapeutics has announced plans to start patient dosing in a pivotal Phase 2b/3 trial testing its experimental…
TP73 Gene Mutations May Be Risk Factor for Sporadic ALS
Rare mutations in the TP73 gene, which is involved in the regulation of a cell’s life cycle, may put a…